MarketLens

Amgen's Biotech Crossroads: Congressional Divergence Amid Patent Cliffs and Pipeline Promise

1 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Merck's Soaring P/E Masks Patent Cliffs and Pipeline Setbacks, Triggering Institutional Exit

1 months ago

What Does Rep. Salazar's Amgen Purchase Signify for Biotech Investors

4 months ago

What's Driving Amgen's Recent Volatility

3 months ago

Why Has Waystar's Stock Fallen So Sharply, and What's Driving the Divergence

5 months ago

Amgen settles shareholder lawsuit claiming it hid $10.7 billion tax bill

Amgen settled a shareholder lawsuit for $74 million, after investors claimed it delayed disclosing a potential $10.7 billion IRS tax bill for six years of underreported taxes.

AMGN

Stock News•1 months ago

uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix

uniQure is shifting gene therapy focus beyond Hemgenix toward CNS pipeline expansion, with AMT-130 as the centerpiece, supported by faster regulatory pathways and a streamlined business model.

QURE

Stock News•1 months ago

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

Big Pharma is spending at a pace not seen since 2019 to replace ~$300B in drugs losing patent protection, fueling biotech acquisitions.

ABBV

Stock News•1 months ago

Amgen or Biogen: Which Biotech Stock Appears Better Poised?

Amgen appears better positioned than Biogen due to its broader portfolio, deeper pipeline, and steadier growth outlook, though both face patent and competition risks.

AMGN